Form D · Other Health Care
March Therapeutics, Inc.
Cambridge, MA · CIK 0001809817
Offering snapshot reported Sep 23, 2022 · SEC filing
- Reported sold
- $20.3M Offering amount: $30.3M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 12, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 23, 2022 | Initial | $20,300,000 | No comparison | 3 | SEC filing |
| Apr 16, 2020 | Initial | $2,719,947 | No comparison | 10 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-459743
Source: Form D, filed Sep 23, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Daniel I. De Wolf | Director |
| Fahim Farzadfard | Director, Executive |
| Habib Haddad | Director |
| Jeong Seuk Kang | Director, Executive |
| Adam Mullinax | Director |
| Clare Ozawa | Director |
Issuer details
Industry: Other Health Care (See others in industry)
Address:
700 Main Street
Cambridge, MA, 02139
Cambridge, MA, 02139